TrialInternational journal of colorectal disease2018

Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: phase II clinical study (The FACOS study).

Chihiro Kosugi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.